OKYO Pharma Limited
OKYOHealthcare|Biotechnology|GB
$1.43
+0.03 (+2.14%)
DCF Value
$0.21
Tangible Book / Share
$0.33
Cash / Share
$0.55
About
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Stock Price
-45.6%(1Y)
1M
+2.9%
3M
-4.0%
6M
-12.3%
YTD
-30.9%
1Y
-46.8%
3Y
-18.3%
5Y
-60.5%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$75.0M
Employees5
CEORobert J. Dempsey
IPO DateMay 17, 2022
Beta0.04
52-Week Range$1.26 – $3.2
Avg Volume92,626
ExchangeNASDAQ
Websiteokyopharma.com
Ownership
Float53.2%
Shares Outstanding52.5M
Recent Insider Trades
BRANCACCIO JOHN PBUY
Jul 21, 20265,000 shares @ $1.48
Dempsey Robert JohnBUY
Jul 22, 202615,000 shares @ $1.54
JACOB GARY SBUY
Jul 21, 20263,500 shares @ $1.40
CERRONE GABRIELE MBUY
Jul 21, 202622,500 shares @ $1.45
CERRONE GABRIELE MBUY
Jul 20, 202625,000 shares @ $1.40
Peers
Recent News
OKYO Pharma to Present at the Stifel 2026 Healthcare Conference
Nov 5, 2026 · globenewswire.com
OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug
Oct 6, 2026 · proactiveinvestors.com
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
Oct 6, 2026 · globenewswire.com
OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
Sep 29, 2026 · globenewswire.com
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
Sep 9, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:26 AM